Sep 13, 2022 / 06:55PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hello, everyone. Good afternoon. My name is Tejas Savant. I cover life science tools and diagnostics here at Morgan Stanley. It's my pleasure to host Veracyte this afternoon, and representing the company, we have Marc and Rebecca, CEO and CFO. It's great to have you both.
Before we dig into questions, quickly the research disclosures. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your sales rep.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystRight. So Marc, maybe just to start, you've been about a year in the hot seat now. What do you view as Veracyte's key accomplishments over the last 12 months? And what are you most excited about heading into '23?
Marc A. Stapley - Veracyte, Inc. - CEO & Director
Thanks, Tejas. Thanks for having us here today as well. Appreciate it. Before I dig